GlassScriptPhysician profile
Sheri Hull
NPI 1336355924
$61,444.18
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $3,238 · 2021: $16K · 2022: $296 · 2023: $818 · 2024: $33.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.44 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $59,215.80 | 2019-2022 | |
| Biogen, INC. | $514.99 | 2020-2023 | Tysabri |
| Alexion Pharmaceuticals, INC. | $323.32 | 2019-2023 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $156.05 | 2020-2021 | |
| Abbvie INC. | $150.91 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $143.73 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $134.37 | 2023 | Austedo Xr, Ajovy |
| Argenx US, INC. | $121.83 | 2023 | Vyvgart |
| Amgen INC. | $107.09 | 2019-2022 | |
| Lundbeck LLC | $102.36 | 2023 | Vyepti |
| Ucb, INC. | $63.64 | 2019-2020 | |
| Horizon Therapeutics Plc | $54.98 | 2022-2023 | Uplizna |
| Pfizer INC. | $53.49 | 2023-2024 | |
| Emd Serono, INC. | $51.00 | 2020 | |
| Acadia Pharmaceuticals INC | $41.44 | 2021-2024 | Nuplazid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $28.09 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $21.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.25 | 2023 | Nuedexta |
| Ani Pharmaceuticals, INC. | $18.09 | 2023 | Purified Cortrophin Gel |
| Allergan, INC. | $17.39 | 2020 | |
| Avion Pharmaceuticals | $14.74 | 2022 | |
| Lilly USA, LLC | $14.24 | 2023 | Reyvow, Emgality |
| Almatica Pharma LLC | $14.11 | 2022 | |
| Assertio Therapeutics, INC. | $13.15 | 2020 | |
| Currax Pharmaceuticals LLC | $12.95 | 2020 | |
| Eisai INC. | $12.26 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Celgene Corporation | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheri Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.